Nivolumab and Relatlimab-rmbw
Class: Antineoplastic Agents
Brands: Opdualag
Introduction
The fixed combination of nivolumab and relatlimab-rmbw is an antineoplastic agent.
Uses for Nivolumab and Relatlimab-rmbw
Nivolumab and relatlimab-rmbw has the following uses:
Nivolumab and relatlimab-rmbw is a fixed-dose combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
Nivolumab and Relatlimab-rmbw Dosage and Administration
General
Nivolumab and relatlimab-rmbw is available in the following dosage form(s) and strength(s):
Injection: 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL) in a single-dose vial.
Dosage
It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Pediatric Patients
Dosage and Administration
Pediatric patients ≥12 years of age weighing ≥40 kg: 480 mg nivolumab and 160 mg relatlimab intravenously every 4 weeks until disease progression or unacceptable toxicity occurs.
Administer nivolumab and relatlimab-rmbw as an intravenous infusion over 30 minutes.
See manufacturer's labeling for dosage modifications for adverse reactions and preparation and administration instructions for the IV infusion.
Adults
Dosage and Administration
Adult patients: 480 mg nivolumab and 160 mg relatlimab intravenously every 4 weeks until disease progression or unacceptable toxicity occurs.
Administer nivolumab and relatlimab-rmbw as an intravenous infusion over 30 minutes.
See manufacturer's labeling for dosage modifications for adverse reactions and preparation and administration instructions for the IV infusion.
Cautions for Nivolumab and Relatlimab-rmbw
Contraindications
None.
Warnings/Precautions
Severe and Fatal Immune-mediated Adverse Reactions
The fixed-combination of nivolumab and relatlimab-rmbw potentially breaks peripheral tolerance and induces immune-mediated adverse reactions (IMARs).
IMARs, which may be severe or fatal, can occur in any organ system or tissue. IMARs can occur at any time after starting treatment with a LAG-3 and PD-1/PD-L1 blocking antibodies. While IMARs usually manifest during treatment, they can also manifest after discontinuation.
Early identification and management of IMARs are essential to ensure safe use. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying IMARs. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected IMARs, initiate appropriate workup to exclude alternative etiologies, including infect...
